UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)
2.40 x 20 2.46 x 2
Post-market by (Cboe BZX)
2.42 +0.03 (+1.26%) 04/17/25 [NASDAQ]
2.40 x 20 2.46 x 2
Post-market 2.40 -0.02 (-0.83%) 18:40 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.33
Day High
2.44
Open 2.37
Previous Close 2.39 2.39
Volume 2,977,200 2,977,200
Avg Vol 4,094,480 4,094,480
Stochastic %K 83.15% 83.15%
Weighted Alpha -36.24 -36.24
5-Day Change +0.35 (+16.91%) +0.35 (+16.91%)
52-Week Range 1.89 - 4.34 1.89 - 4.34
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 721,131
  • Shares Outstanding, K 297,988
  • Annual Sales, $ 28,830 K
  • Annual Income, $ -162,860 K
  • EBIT $ -224 M
  • EBITDA $ -127 M
  • 60-Month Beta 0.50
  • Price/Sales 24.70
  • Price/Cash Flow N/A
  • Price/Book 0.67

Options Overview Details

View History
  • Implied Volatility 182.72% ( +81.86%)
  • Historical Volatility 81.46%
  • IV Percentile 94%
  • IV Rank 49.62%
  • IV High 352.21% on 04/08/25
  • IV Low 15.78% on 05/10/24
  • Put/Call Vol Ratio 0.49
  • Today's Volume 127
  • Volume Avg (30-Day) 306
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 27,131
  • Open Int (30-Day) 26,725

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 5
  • High Estimate -0.14
  • Low Estimate -0.20
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.89 +28.04%
on 04/07/25
Period Open: 2.54
2.60 -6.92%
on 03/25/25
-0.12 (-4.72%)
since 03/17/25
3-Month
1.89 +28.04%
on 04/07/25
Period Open: 2.97
3.68 -34.24%
on 01/22/25
-0.55 (-18.52%)
since 01/17/25
52-Week
1.89 +28.04%
on 04/07/25
Period Open: 3.92
4.34 -44.24%
on 05/28/24
-1.50 (-38.27%)
since 04/17/24

Most Recent Stories

More News
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2024.

ABCL : 2.42 (+1.26%)
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript

ABCL earnings call for the period ending September 30, 2024.

ABCL : 2.42 (+1.26%)
Should You Follow Insider Buying on This Biotech Penny Stock?

With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.

ABCL : 2.42 (+1.26%)
LLY : 839.96 (+14.30%)
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript

ABCL earnings call for the period ending June 30, 2024.

ABCL : 2.42 (+1.26%)
1 Billionaire-Backed Penny Stock With 421% Upside

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

AAPL : 196.98 (+1.39%)
ABCL : 2.42 (+1.26%)
MRK : 78.00 (+2.01%)
LLY : 839.96 (+14.30%)
AMZN : 172.61 (-0.99%)
PFE : 22.14 (+0.45%)
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

ABCL : 2.42 (+1.26%)
MRK : 78.00 (+2.01%)
LLY : 839.96 (+14.30%)
OPHLY : 4.1500 (+4.80%)
FATE : 1.1100 (+5.71%)
PFE : 22.14 (+0.45%)
Down 57%, Is AbCellera Biologics a Buy on the Dip?

Wall Street analysts say this drug developer can more than double your money.

ABCL : 2.42 (+1.26%)
LLY : 839.96 (+14.30%)
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript

ABCL earnings call for the period ending March 31, 2024.

ABCL : 2.42 (+1.26%)
3 AI-Driven Drug Stocks to Buy Before They Breakout

The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven...

NVDA : 101.49 (-2.87%)
GOOGL : 151.16 (-1.42%)
ABCL : 2.42 (+1.26%)
LLY : 839.96 (+14.30%)
ABSI : 3.09 (+1.31%)
NVS : 110.86 (+1.17%)
SDGR : 25.75 (+2.14%)
GS : 509.49 (+2.09%)
REGN : 563.16 (+2.53%)
MRNA : 24.72 (-1.89%)
AMZN : 172.61 (-0.99%)
BMY : 49.23 (-0.26%)
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2023.

ABCL : 2.42 (+1.26%)

Business Summary

AbCellera Biologics Inc. is a technology company which searches, decodes and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera Biologics Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 2.57
2nd Resistance Point 2.51
1st Resistance Point 2.46
Last Price 2.42
1st Support Level 2.35
2nd Support Level 2.29
3rd Support Level 2.24

See More

52-Week High 4.34
Fibonacci 61.8% 3.40
Fibonacci 50% 3.11
Fibonacci 38.2% 2.83
Last Price 2.42
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro